Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 19.4% on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. Approximately 215,053 shares changed hands during trading, a decline of 58% from the average daily volume of 513,395 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$22.59 million, a price-to-earnings ratio of -4.52 and a beta of 0.20. The stock’s 50 day moving average price is C$0.19 and its two-hundred day moving average price is C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What Are Growth Stocks and Investing in Them
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Use the MarketBeat Stock Screener
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Which Wall Street Analysts are the Most Accurate?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
